Ilias Kainis
Athens, ESYE31, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
29-mRNA host response signatures for classification of bacterial infection, viral infection and disease progression in COVID-19 pneumonia: a post hoc analysis of the SAVE-MORE randomized clinical trial.
Journal: Intensive care medicine experimental
Published: January 12, 2025
Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial.
Journal: Critical care (London, England)
Published: January 11, 2024
Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial.
Journal: EClinicalMedicine
Published: October 10, 2022
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia.
Journal: Cytokine
Published: October 09, 2022
Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.
Journal: Cell reports. Medicine
Published: November 16, 2021
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Journal: Nature medicine
Published: October 09, 2021
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Journal: Nature medicine
Published: June 22, 2021
Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival.
Journal: Oncology research
Published: April 09, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026